Dirozalkib

地罗阿克

Report date: 2026/04/14 20:00:15
NME

Base Information

Drug NameDirozalkib
Drug Alias Name达希替尼Dexitinib轩菲宁XZP-3621XZP-3621-1001
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAnaplastic lymphoma kinase inhibitorsProto-oncogene tyrosine-protein kinase ROS inhibitors
TargetsAnaplastic lymphoma kinaseProto-oncogene tyrosine-protein kinase ROS
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsCarcinoma, Non-Small-Cell Lung
Approved Indications in ChinaCarcinoma, Non-Small-Cell Lung
Original Approved Country/TerritoryMainland China
Original Approved Date2025/08/19
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesShandong Xuanzhu Pharmaceutical Technology Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesBoston Oncology CGT Holding Co ltdXuanzhu (Shijiazhuang) Biotechnology Co Ltd
Inactive CompaniesShandong Xuanzhu Pharmaceutical Technology Co LtdXuanzhu (HK) Biopharmaceutical Ltd
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A